X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
HTL’744 (HTL0033744) is a potent, selective and gut-restricted prostaglandin EP4 receptor agonist, which is being evaluated for the treatment of inflammatory bowel diseases like crohn’s disease.
Lead Product(s): HTL0033744
Therapeutic Area: Gastroenterology Product Name: HTL’744
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 20, 2024
Details:
The collaboration aims to focus on the development of HTL0048149, which is a GPR52 agonist. Currently it being evaluated with patients for the treatment of Schizophrenia.
Lead Product(s): HTL0039732
Therapeutic Area: Psychiatry/Psychology Product Name: HTL0039732
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $732.5 million Upfront Cash: $27.3 million
Deal Type: Collaboration March 11, 2024
Details:
NBI-1117569, a muscarinic M4-preferring agonist, small molecule drug candidate in oral form being developed for the treatment of neurological diseases.
Lead Product(s): NBI-1117569
Therapeutic Area: Neurology Product Name: NBI-1117569
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Neurocrine Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
The company successful identification, validation and nomination of a first G protein-coupled receptor (GPCR) target to enter a therapeutic discovery program for gastrointestinal diseases.
Lead Product(s): Gut-brain Axis Based Drug
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2023
Details:
The collaboration aims to discover and develop novel medicines that modulate GPCR targets of interest to Genentech. The discovery-based milestone is related to progression of a potential first-in-class project targeting an undisclosed G protein-coupled receptor.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: Genentech
Deal Size: $1,026.0 million Upfront Cash: $26.0 million
Deal Type: Collaboration October 31, 2023
Details:
Sosei Heptares gained Japan and Asia-Pacific (ex-China) rights to ACT-541468 (daridorexant), a dual orexin receptor antagonist being developed for the treatment of adult patients with insomnia, from Idorsia.
Lead Product(s): Daridorexant HCl
Therapeutic Area: Sleep Product Name: Quviviq
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Idorsia Pharmaceuticals
Deal Size: $440.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
The collaboration combines Sosei's leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform to drive novel drug discovery for a second neurological disease target.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Small molecule
Partner/Sponsor/Collaborator: PharmEnable
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration October 10, 2023
Details:
NBI-1117570 is an investigational, oral, muscarinic M1/M4 dual agonist. Muscarinic receptors are fundamental to activating signaling pathways in the brain.
Lead Product(s): NBI-1117570
Therapeutic Area: Neurology Product Name: NBI-1117570
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Neurocrine Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies.
Lead Product(s): HTL0039732,Atezolizumab
Therapeutic Area: Oncology Product Name: HTL0039732
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cancer Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
Through the acquisition, Sosei also gains assignment of Pivlaz (clazosentan), for the treatment of cerebral vasospasm, and license rights to daridorexant in the Asia Pacific (ex-China) region.
Lead Product(s): Clazosentan Sodium
Therapeutic Area: Neurology Product Name: Pivlaz
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Idorsia Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
